Please login to the form below

Not currently logged in
Email:
Password:

Merck/Ono collaborate on MS and cancer

Merck Serono and Ono Pharmaceutical are to work together to develop and market new treatments for both multiple sclerosis and cancer

Merck Serono and Ono Pharmaceutical are to work together to develop and market new treatments for both multiple sclerosis (MS) and cancer.

The deal involves the investigational drug, ONO-4641, which is currently in phase II development for the treatment of MS, and Stimuvax, an investigational cancer therapy in phase III development.

Merck will acquire worldwide exclusive licence rights for ONO-4641 outside Japan, Korea and Taiwan, with Ono receiving 1.5bn yen (about €14m) in upfront payment and the potential of additional milestones. The drug was originally discovered and developed by Japan-based Ono.

In return, Ono will gain co-development and co-marketing rights of Merck's Stimuvax in Japan. Stimuvax is an investigational non-small cell lung cancer (NSCLC) immunotherapy. Merck will receive an upfront payment of €5m, with additional financial terms not disclosed.

Merck obtained the exclusive worldwide licensing rights for Stimuvax from US-based pharmaceutical firm Oncothyreon.

4th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics